Skip to content

Evaluation of the effect of pretreatment of E2 and OCP in Antagonist cycle In IVF cycles.

Evaluation of the effect of pretreatment of E2 and OCP before Antagonist cycle on IVF outcome.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017020520351N9
Enrollment
195
Registered
2017-02-21
Start date
2017-02-19
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility associated with anovulation. Female infertility, unspecified

Interventions

Intervention 1: In group without intervention ( Control): only antagonist 25 miligram daily is administrated from the second day of the cycle. In all three groups of patients after 6 days of treatmen
Treatment - Drugs
In group without intervention ( Control): only antagonist 25 miligram daily is administrated from the second day of the cycle. In all three groups of patients after 6 days of treatment, vaginal ultra
In intervention group 1: daily treatment is a pill (OCP) for 10 days and 10-12 days before the last cycle. In all three groups of patients after 6 days of treatment, vaginal ultrasound will be done ev
In intervention group 2: daily treatment is a Estradiol Pill for 10 days and before the start of Antagonist administration. In all three groups of patients after 6 days of treatment, vaginal ultraso

Sponsors

Vice Chancellor for Research, Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: women with 20-35 years old; prior IVF less than 2; AFC>4; FSH<10; without any pathology in ovary or endometrioma more than 1cm; without any hydrosalpinx. Exclusion criteria: PCOS; pathology in uterus or ovary ( myoma larger than 5 cm); absence of vaginal bleeding until 6 days after disconnection of OCP or E2; lack of permission of patients.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Oocyte number. Timepoint: Six days after treatment. Method of measurement: Vaginal sonography.;Number of induction ovulation. Timepoint: After treatment. Method of measurement: Transvaginal sonography.

Secondary

MeasureTime frame
Chemical pregnancy. Timepoint: 14 days after embryo transfer. Method of measurement: B-HCG Test.;Clinical pregnancy. Timepoint: Three weeks after do positive of pregnancy teset. Method of measurement: Transvaginal sonography.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Bakhtiari

Reproductive Health Research Center

bakhtiyari1355@gmail.com+98 21 6658 1658

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026